Bristol Myers Squibb Finalizes Acquisition of 2Seventy Bio

Transaction Details and Shareholder Returns

The independent journey of biotechnology firm 2Seventy Bio has concluded following its full acquisition by pharmaceutical giant Bristol Myers Squibb. The deal, which resulted in the immediate delisting of 2Seventy Bio from the Nasdaq exchange, provided shareholders with a definitive cash exit of $5.00 per share.

On May 13, 2025, Bristol Myers Squibb formally completed the acquisition of all outstanding 2Seventy Bio shares in an all-cash transaction valued at $5.00 per share. This price represented a substantial 88% premium over the closing price of $2.66 recorded on March 7, 2025, just before initial deal announcements surfaced. For investors in the specialized cell therapy sector, which has faced significant market challenges, this transaction provided a certain exit valuation.